03:55 AM EDT, 08/30/2024 (MT Newswires) -- Hutchmed ( HCM ) said Friday it has withdrawn its supplemental new drug application in China for fruquintinib in combination with paclitaxel for the potential treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma.

Hutchmed ( HCM ) said a review of data and consultations with regulators suggested that the treatment is unlikely to win approval and the company "will evaluate a new route forward."

The latest phase 3 testing of the treatment showed benefits in meeting some endpoints, it failed to show "statistically significant" improvement in meeting the second primary endpoint of median overall survival, the company said.

Price: 18.00, Change: +0.24, Percent Change: +1.35